行情

XNCR

XNCR

Xencor
NASDAQ

实时行情|Nasdaq Last Sale

35.98
+0.02
+0.06%
盘后: 35.98 0 -0.01% 16:09 11/15 EST
开盘
36.14
昨收
35.96
最高
36.35
最低
35.62
成交量
27.86万
成交额
--
52周最高
46.33
52周最低
27.75
市值
20.41亿
市盈率(TTM)
60.80
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

XNCR 新闻

  • Edited Transcript of XNCR earnings conference call or presentation 5-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.1天前
  • Xencor to Present at Upcoming Investor Conferences
  • Business Wire.3天前
  • Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting
  • Business Wire.11/06 14:00
  • Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/06 04:21

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

XNCR 简况

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
展开

Webull提供Xencor Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。